Plain-English translation of NCT03793517 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , combined with standard pre-transplant chemotherapy drugs, can help people with high-risk acute leukemia have better outcomes after a stem cell transplant. The trial focuses on patients whose cancer is still detectable right before transplant—a situation that carries higher risk. Researchers will monitor how well this medication combination works and how safe it is.
Some people with acute leukemia still have cancer cells that can be detected just before receiving a stem cell transplant, which means their disease is harder to treat. This trial is testing whether adding this medication to the standard pre-transplant preparation can eliminate more cancer cells and reduce the chance of the disease coming back.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication for two days, followed by several days of standard chemotherapy drugs to prepare your body for the stem cell transplant. After transplant, you would have bone marrow samples taken at regular visits—at 1, 2, 3, 4.5, 6, 9, and 12 months after transplant, then every 6 months for at least 5 years—to check whether cancer cells remain and how well the transplant is working.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China